Six-years survival and predictors of mortality after CABG using cold vs. warm blood cardioplegia in elective and emergent settings

Table 6 Multivariate analysis, primary endpoint: 30-days mortality

Multivariate analysis, primary endpoint: 30-days mortality (n = 45)
Variable	O.R.	95 %-C.I.	p-value
HLP	0.39	(0.19 – 0.79)	0.009
AF	3.33	(1.49 – 7.47)	0.003
3 V–CAD	0.36	(0.16 – 0.83)	0.016
COPD	0.26	(1.05 – 6.21)	0.038
PAD	2.51	(1.13 – 5.55)	0.023
Statin	0.38	(0.18 – 0.80)	0.010
Antiplatelet.	1.99	(0.95 – 4.17)	0.070
EF <40 %	3.66	(1.79 – 7.52)	<0,001
Variable used in multivariable analysis:
Female
HT
pulm. HT
HLP
Diab. mellitus
AF
3 V–CAD
LMS
COPD
PAD
Smoker
Crea >2
Renal insuff. preop Crea <2
CVA
Beta-blocker
Statin
Antiplatelet.
EF <40 %
IABP preop

AF Atrial fibrillation, CVA cerebrovascular accident, HLP Hyperlipidemia, HT Hypertension, PAD peripherial artery disease, LMS left main stenosis

ISSN: 1749-8090